WO2003082330A1 - Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles - Google Patents

Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles Download PDF

Info

Publication number
WO2003082330A1
WO2003082330A1 PCT/JP2003/003694 JP0303694W WO03082330A1 WO 2003082330 A1 WO2003082330 A1 WO 2003082330A1 JP 0303694 W JP0303694 W JP 0303694W WO 03082330 A1 WO03082330 A1 WO 03082330A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
protein nanoparticles
drug
hollow protein
hollow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/003694
Other languages
English (en)
French (fr)
Inventor
Shunichi Kuroda
Katsuyuki Tanizawa
Akihiko Kondo
Masakazu Ueda
Masaharu Seno
Toshihide Okajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Japan Science and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency, Japan Science and Technology Corp filed Critical Japan Science and Technology Agency
Priority to US10/509,249 priority Critical patent/US7951379B2/en
Priority to KR1020047015430A priority patent/KR100635870B1/ko
Priority to EP03715409.3A priority patent/EP1491210B1/en
Publication of WO2003082330A1 publication Critical patent/WO2003082330A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184Virus capsids or envelopes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Botany (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2003/003694 2002-03-29 2003-03-26 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles Ceased WO2003082330A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/509,249 US7951379B2 (en) 2002-03-29 2003-03-26 Hollow nanoparticle of NBsAg large protein for drug delivery
KR1020047015430A KR100635870B1 (ko) 2002-03-29 2003-03-26 항체를 제시하는 단백질 중공 나노입자를 사용하는치료약제 및 단백질 중공 나노입자
EP03715409.3A EP1491210B1 (en) 2002-03-29 2003-03-26 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002097424 2002-03-29
JP2002-97424 2002-03-29
JP2003-45088 2003-02-21
JP2003045088A JP4212921B2 (ja) 2002-03-29 2003-02-21 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子

Publications (1)

Publication Number Publication Date
WO2003082330A1 true WO2003082330A1 (en) 2003-10-09

Family

ID=28677594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/003694 Ceased WO2003082330A1 (en) 2002-03-29 2003-03-26 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles

Country Status (5)

Country Link
US (1) US7951379B2 (ja)
EP (1) EP1491210B1 (ja)
JP (1) JP4212921B2 (ja)
KR (1) KR100635870B1 (ja)
WO (1) WO2003082330A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049824A1 (ja) * 2003-11-21 2005-06-02 Japan Science And Technology Agency 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用
WO2007037273A1 (ja) * 2005-09-28 2007-04-05 National University Corporation Kobe University 細胞膜透過ペプチドを提示したナノ粒子による細胞への物質導入
WO2008018555A1 (en) * 2006-08-11 2008-02-14 National University Corporation Okayama University HBsAg PARTICLE HAVING LOW ANTIGENICITY AND METHOD FOR PRODUCTION THEREOF
WO2013147232A1 (ja) * 2012-03-30 2013-10-03 国立大学法人名古屋大学 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059746A1 (en) * 2005-09-14 2007-03-15 Japan Science And Technology Agency Substance carrier using hollow nanoparticle of hepatitis B virus protein and liposome, and method of introducing substance into cell
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
EP2262489A2 (en) * 2008-02-28 2010-12-22 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Hollow nanoparticles and uses thereof
JP2010096677A (ja) * 2008-10-17 2010-04-30 Toray Ind Inc 抗体/抗原結合能を有する高感度免疫学測定用ナノ粒子
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
MX385842B (es) 2013-09-18 2025-03-18 Aura Biosciences Inc Conjugados de partículas de tipo virus y uso de las mismas.
WO2017075440A1 (en) 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy
IL269986B2 (en) 2017-04-12 2024-06-01 Aura Biosciences Inc Targeted combination therapy
AR120891A1 (es) 2019-12-23 2022-03-30 Mitsubishi Tanabe Pharma Corp Proteína rsv f mutante y su uso
JP7787563B2 (ja) * 2022-01-12 2025-12-17 株式会社ビークル 新型コロナウイルスの検出に使用可能な融合タンパク質およびその用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006929A1 (en) * 1992-09-17 1994-03-31 Merck Patent Gmbh Small cell lung carcinoma specific antibody and antigen
WO1996001126A1 (en) * 1994-07-06 1996-01-18 Immunomedics, Inc. Multi-stage cascade boosting vaccine
EP0706799A2 (en) * 1994-09-16 1996-04-17 MERCK PATENT GmbH Immunoconjugates II
WO2001064930A1 (en) * 2000-02-28 2001-09-07 Japan Science And Technology Corporation Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504088A (ja) 1992-09-17 1996-05-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍特異性抗体および抗原
US7354587B1 (en) * 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
JP2000503003A (ja) 1995-12-22 2000-03-14 イムノメディクス,インコーポレイテッド 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
WO1998007410A1 (en) * 1996-08-19 1998-02-26 Vivorx Pharmaceuticals, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
WO1999040214A2 (en) * 1998-02-09 1999-08-12 Genzyme Corporation Nucleic acid delivery vehicles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006929A1 (en) * 1992-09-17 1994-03-31 Merck Patent Gmbh Small cell lung carcinoma specific antibody and antigen
WO1996001126A1 (en) * 1994-07-06 1996-01-18 Immunomedics, Inc. Multi-stage cascade boosting vaccine
EP0706799A2 (en) * 1994-09-16 1996-04-17 MERCK PATENT GmbH Immunoconjugates II
WO2001064930A1 (en) * 2000-02-28 2001-09-07 Japan Science And Technology Corporation Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHMAD I. ET AL.: "Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro", CANCER RES., vol. 52, no. 17, 1992, pages 4817 - 4820, XP002959035 *
NAKAMURA Y. ET AL.: "Development of novel whole-cell immunoadsorbents by yeast surface display of the IgG-binding domain", APPL. MICROBIOL. BIOTECHNOL., vol. 57, no. 4, 2001, pages 500 - 505, XP002969302 *
See also references of EP1491210A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049824A1 (ja) * 2003-11-21 2005-06-02 Japan Science And Technology Agency 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用
WO2007037273A1 (ja) * 2005-09-28 2007-04-05 National University Corporation Kobe University 細胞膜透過ペプチドを提示したナノ粒子による細胞への物質導入
WO2008018555A1 (en) * 2006-08-11 2008-02-14 National University Corporation Okayama University HBsAg PARTICLE HAVING LOW ANTIGENICITY AND METHOD FOR PRODUCTION THEREOF
JP5147697B2 (ja) * 2006-08-11 2013-02-20 国立大学法人 岡山大学 低抗原性のHBsAg粒子及びその作製法
WO2013147232A1 (ja) * 2012-03-30 2013-10-03 国立大学法人名古屋大学 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル
JP5458286B1 (ja) * 2012-03-30 2014-04-02 国立大学法人名古屋大学 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル

Also Published As

Publication number Publication date
JP2004002313A (ja) 2004-01-08
US20060088536A1 (en) 2006-04-27
JP4212921B2 (ja) 2009-01-21
EP1491210A4 (en) 2010-10-13
KR100635870B1 (ko) 2006-10-18
US7951379B2 (en) 2011-05-31
EP1491210A1 (en) 2004-12-29
KR20040105815A (ko) 2004-12-16
EP1491210B1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
WO2003082330A1 (en) Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
White et al. Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis
DE60138641D1 (de) Herstellung von mikrokügelchen
CY1112110T1 (el) Κυκλικο μοριο dna το οποιο διαθετει μια συμβατικη αφετηρια αντιγραφης, η διαδικασια παρασκευης του και η χρηση του στην γονιδιακη θεραπεια
WO2004084939A8 (en) Hiv-peptide-carrier-conjugates
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
EP1775342A4 (en) ANTITUM-AGENT WITH MINUS STRAND RNA VIRUS
WO2003072711A3 (en) Method of using modified oligonucleotides for hepatic delivery
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2006037787A3 (en) Vlp-antigen conjugates and their uses as vaccines
Grohmann et al. Targeted protein degradation at the host–pathogen interface
DE50310081D1 (de) Tumorspezifische erkennungsmoleküle
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
WO2005000240A3 (en) Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
WO2005092073A3 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
WO2001087350A3 (en) Treatment of human papillomavirus (hpv)-infected cells
Dai et al. Single-stranded RNA origami-based epigenetic immunomodulation
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
WO2003082345A1 (en) Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith
EP1712243A4 (en) GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE
Iannazzo et al. Graphene-based materials as nanoplatforms for antiviral therapy and prophylaxis
WO2005113005A3 (en) Transcutaneous and/or transdermal transport of materials
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020047015430

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006088536

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10509249

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003715409

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047015430

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003715409

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10509249

Country of ref document: US